Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe First Affiliated Hospital with Nanjing Medical University

About this trial

To investigate whether RFCA is superior to AADs in AF patients with HFpEF on the basis of optimized anti-heart-failure drug therapy regarding their longterm clinical outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Symptomatic paroxysmal or persistent atrial fibrillation

CHADS2-VASc score≥ 2

Conform to the diagnosis of HFpEF

NYHA II-IV level;

Disqualifiers

A life expectancy below 2 years due to any non-cardiovascular condition

Reversible atrial fibrillation, such as hyperthyroidism or hypokalemia-related atrial fibrillation

Prior atrial fibrillation ablation

Left atrial size≥ 55 mm

Trial design

Design model

Parallel

Treatments tested in this trial

  • Radiofrequency catheter ablation (RFCA)

    Procedure/Surgery

    Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.

  • Medical Therapy

    Drug

    AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.

Treatment groups

436 Participants
are divided into 2 treatment groups
Group A: Radiofrequency catheter ablation (RFCA)Experimental treatment 1 intervention
Group B: Medical therapyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Composite endpoint of worsening heart failure requiring unplanned hospitalizations or urgent visits, and cardiovascular death (Time-to-first event analysis)

Time frame
From randomization until completion of the planned follow-up, up to 36 months

Secondary outcomes

1

Time to hospitalization or urgent visits for heart failure

Worsening heart failure includes worsening heart failure requiring unplanned hospitalization and worsening heart failure requiring urgent visits.

Time frame
From randomization until completion of the planned follow-up, up to 36 months
2

Time to hospitalization for heart failure

In addition to signs and symptoms of HF, the patient should also receive treatment specifically directed at HF, including at least 1 of the following: 1) significant augmentation in oral diuretic therapy; 2) initiation of intravenous diuretic (even a single dose) or vasoactive agent (eg, vasodilator, vasopressor, or inotropic therapy); or 3) mechanical circulatory support or fluid removal. Unplanned hospitalization is defined as any unscheduled hospital admission with a length of stay that either exceeds 24 h or crosses a calendar day, and not planned by the investigators. In case the hospitalization is classified as planned by the Investigator and the time interval between the decision to admit and the admission is less than 24 hours, the End Point and Adverse Event Committee will give final classification concerning planned or unplanned.

Time frame
From randomization until completion of the planned follow-up, up to 36 months
3

Time to urgent visits for heart failure

Worsening of Heart Failure Requiring Unplanned Urgent Visits Patients have an urgent, unscheduled office or emergency visit for HF with signs, symptoms, and diagnostic testing results identical to those already described for an HF hospitalization. The patient must also (with the exception of significant augmentation in oral diuretic therapy) require therapy similar to that previously described for an HF hospitalization.

Time frame
From randomization until completion of the planned follow-up, up to 36 months
4

Time to cardiovascular death

All deaths due to cardiovascular reasons and all heart transplants because of terminal HF. Deaths due to worsening of HF, acute coronary syndrome, cerebrovascular accident.

Time frame
From randomization until completion of the planned follow-up, up to 36 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.